Altre lingue RepliCel Life Sciences Inc. Toronto S.E.

Azioni

RP

CA76027P4006

Tempo differito Toronto S.E. Altri mercati azionari 17:00:00 16/04/2024			Variaz. 5gg	Var. 1 gen.
0,055 ^CAD	-.--%		-21,43%	-15,38%

17/05	RepliCel Life Sciences Inc. riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023	CI
2023	RepliCel Life Sciences Inc. riporta i risultati degli utili per il terzo trimestre e i nove mesi conclusi il 30 settembre 2023	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

RepliCel Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	17/05
RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	28/11
RepliCel Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/10/23
Replicel Life Sciences Inc. Announces That Peter Lowry Will Not Be Standing for Re-Election as A Director	30/08/23
RepliCel Life Sciences Inc. Appoints Jamie Mackay to the Board of Directors	17/08/23
RepliCel Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	30/05/23
RepliCel Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	02/05/23
RepliCel Life Sciences Inc. Auditor Raises 'Going Concern' Doubt	01/05/23
RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	29/11/22
RepliCel Life Sciences Inc. Announces Executive Changes	28/11/22
RepliCel Life Sciences Inc. Announces Executive Changes	28/11/22
RepliCel Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	29/08/22
RepliCel Life Sciences Inc. Receives Test Results Showing That Cells Injected Through the DermaPrecise	02/08/22
RepliCel Life Sciences Inc. Receives and Analyzes All Data and Images from Independent Laboratory Testing of the Dermaprecise Injector Prototype	26/07/22
RepliCel Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	07/07/22
RepliCel Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	28/06/22
RepliCel Life Sciences Inc. Auditor Raises 'Going Concern' Doubt	28/06/22
RepliCel Life Sciences Inc. Terminates License Agreement with Shiseido	21/12/21
RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	29/11/21
Replicel Life Sciences Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	30/08/21

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue RepliCel Life Sciences Inc. Toronto S.E.

Azioni

RP

CA76027P4006

Altre lingue

Filtri